Lazard Asset Management LLC Prothena Corp Public LTD CO Transaction History

Lazard Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$16.73 - $24.79 $705,554 - $1.05 Million	42,173 New	42,173 $705,000
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $137,511 - $222,673	4,256 New	4,256 $154,000
Q1 2023 May 15, 2023	BUY	$46.97 - $58.27 $57,679 - $71,555	1,228 New	1,228 $59,000
Q1 2022 May 13, 2022	BUY	$30.27 - $49.22 $19,887 - $32,337	657 Added 61.06%	1,733 $63,000
Q4 2021 Feb 09, 2022	BUY	$42.11 - $73.26 $6,653 - $11,575	158 Added 17.21%	1,076 $53,000
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $44,247 - $72,421	918 New	918 $65,000

205

45.5M

583K

195K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $665M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.